- Home
- CBRE vs INAB Comparison
CBRE vs INAB Comparison
Compare CBRE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- INAB
- Stock Information
- Founded
- CBRE 1906
- INAB 2016
- Country
- CBRE United States
- INAB United States
- Employees
- CBRE N/A
- INAB 18
- Industry
- CBRE Real Estate
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- CBRE Finance
- INAB Health Care
- Exchange
- CBRE Nasdaq
- INAB Nasdaq
- Market Cap
- CBRE 47.3B
- INAB 9.1M
- IPO Year
- CBRE 2004
- INAB 2021
- Fundamental
- Price
- CBRE $163.60
- INAB $2.02
- Analyst Decision
- CBRE Buy
- INAB Strong Buy
- Analyst Count
- CBRE 9
- INAB 2
- Target Price
- CBRE $165.22
- INAB $108.00
- AVG Volume (30 Days)
- CBRE 1.5M
- INAB 52.4K
- Earning Date
- CBRE 10-23-2025
- INAB 11-11-2025
- Dividend Yield
- CBRE N/A
- INAB N/A
- EPS Growth
- CBRE 19.77
- INAB N/A
- EPS
- CBRE 3.57
- INAB N/A
- Revenue
- CBRE $38,104,000,000.00
- INAB N/A
- Revenue This Year
- CBRE $14.30
- INAB N/A
- Revenue Next Year
- CBRE $10.11
- INAB N/A
- P/E Ratio
- CBRE $46.38
- INAB N/A
- Revenue Growth
- CBRE 14.96
- INAB N/A
- 52 Week Low
- CBRE $108.45
- INAB $1.91
- 52 Week High
- CBRE $167.56
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- CBRE 57.41
- INAB 40.36
- Support Level
- CBRE $163.39
- INAB $1.99
- Resistance Level
- CBRE $167.56
- INAB $2.20
- Average True Range (ATR)
- CBRE 2.59
- INAB 0.11
- MACD
- CBRE -0.35
- INAB -0.01
- Stochastic Oscillator
- CBRE 65.23
- INAB 28.21
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.